Statement: the primary clinical trial most commonly resulted in adverse events of blood clots
Primary_evidence: Adverse Events 1:   Total: 14/41 (34.15%)   Anemia 1/41 (2.44%)   Febrile neutropenia 1/41 (2.44%)   Eye disorders - Other, Visual disturbance 1/41 (2.44%)   Abdominal pain 1/41 (2.44%)   Constipation 1/41 (2.44%)   Nausea 1/41 (2.44%)   Fever 1/41 (2.44%)   Pain 1/41 (2.44%)   Skin infection 2/41 (4.88%)   Alkaline phosphatase increased 1/41 (2.44%)   Aspartate aminotransferase increased 1/41 (2.44%)